Development of the large-scale vaccine production process remains an inherently challenging undertaking. Given this complexity, it is more important than ever for vaccine manufacturers to collaborate with experienced technology providers. Such partners can provide critical support from development through manufacturing, helping to eliminate bottlenecks and accelerating production of urgently needed vaccines.
Collaborating to accelerate vaccine manufacturing
Latest NewsDevelopment of the large-scale vaccine production process remains an inherently challenging undertaking. Given this complexity, it is more important than ever for vaccine manufacturers to collaborate with experienced technology providers. Such partners can provide critical support from development through manufacturing, helping to eliminate bottlenecks and accelerating production of urgently needed vaccines.
Urgent need for medical data network across borders
OpinionThe COVID-19 pandemic is putting our health systems in Europe to the test. Capacity bottlenecks are becoming apparent, as are long-neglected investments in modern infrastructure. As the pandemic does not stop at national borders, cross-border healthcare solutions are more urgent than ever.
3,000+ experts discuss bioeconomy globally
Latest NewsMore than 3,000 attendees are participating in the Global Bioeconomy Summit, currently taking place virtually until 20th November. Today, the plenary program and the livestream of the conference kicked-off.
EU COVID-19 antibody ready for clinical trials
Latest NewsAs investments into COVID-19 therapeutics is no EU priority, development is lagging behind the US. Now, CORAT Therapeutics candidate COR101 is set to enter clinical testing.
Management changes at BioChek
AppointmentsThomas Struckmeyer will join the BioChek Group based in Reeuwijk as new CEO from mid-December. He succeeds Barend van Dam, who will assume the position of CEO of the BioChek Group.
COVID-19: Moderna reports promising interim results
Latest NewsAfter BioNTech SE reported that its COVID-19 vaccine candidate BNT162b2 was over 90% efficient in a Phase III trial, Moderna Inc announced an efficacy of 94.5%.
Evotec expanding at Milton Park campus
Latest NewsEvotec SE is set to expand the company’s existing campus in Milton Park/Abingdon, UK, into a major, fully-integrated drug discovery and development centre.
Pfizer/BioNTech sign vaccine contract with EC
Latest NewsPfizer and Biontech SE have reached an agreement with the European Commission to supply 200 million doses of their mRNA-based COVID-19 vaccine candidate.
1,800+ experts will join the Global Bioeconomy Summit
Latest NewsMore than 1,800 attendees already registered for the Global Bioeconomy Summit 2020. The conference takes place virtually from November 16 to 20.
BioNTech reports high efficacy of COVID-19 vaccine
Latest NewsInterim data on BioNtech’s/Pfizer’s COVID-19 vaccine candidate BNT162b2 suggest an efficacy of more than 90% – 30% better than required by the FDA.